Torcetrapib + atorvastatin Pfizer

Current Opinion in Investigational Drugs

Volumn 6, Issue 9, 2005, Pages 944-950

  Burnett, John R ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ATORVASTATIN; CETI 1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PLACEBO; SC 795; SCH 50678; SCH 50679; SCH 50680; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AMNESIA; ASTHENIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPEPSIA; ENZYME INHIBITION; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PAIN; PATENT; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SWEATING;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; DRUG COMBINATIONS; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; PYRROLES; QUINOLINES;

EID: 24644475239     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 393182 Pfizer optimistic for the future. Pfizer Inc PRESS RELEASE 2000 December 12
2. 482137 Discovery of CP-529,414: A potent synthetic inhibitor of human plasma cholesteryl ester transfer protein (CETP). Ruggeri RB, Wester RT, Magnus-Aryitey G ACS 2003 225 MEDI Abs 156
3. 484149 Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia. Inazu A, Mabuchi H. CURR OPIN INVESTIG DRUGS 2003 4 3 291-297
4. 499537 Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein. Reinhard EJ, Wang JL, Durley RC, Fobian YM, Grapperhaus ML, Hickory BS, Massa MA, Norton MB, Promo MA, Tollefson MB, Vernier WF et al J MED CHEM 2003 46 11 2152-2168
5. 502779 The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Watts GF CLIN SCI 2002 103 6 595-597
6. 504410 Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR J CLIN INVEST 1996 97 12 917-923
7. 504568 High density lipoproteins and atherosclerosis. Role of cholesterol efflux and reverse cholesterol transport. von Eckardstein A, Nofer JR, Assmann G ARTERIOSCLER THROMB VASC BIOL 2001 21 1 13-27
8. 504683 Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR ARTERIOSCLER THROMB VASC BIOL 2003 23 2 160-167
9. 510165 Pfizer Inc third-quarter 2003 performance report. Pfizer Inc PRESS RELEASE 2003 October 22
10. 511519 Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagan P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Shaeldon S, Grines CL, Halpern S et al J AM MED ASSOC 2003 290 17 2292-2300
11. 523742 Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multiclose study of torcetrapib. Clark RW, Sutfin A, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ ARTERIOSCLER THROMB VASC BIOL 2004 24 3 490-497
12. 526573 High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR AM J MED 1977 62 5 707-714
13. 526575 Regulation of reverse cholesterol transport and clinical implications. Rader DJ AM J CARDIOL 2003 92 4A 42J-49J.
14. 526969 JTT-705 Japan Tobacco. Linders JTM CURR OPIN INVESTIG DRUGS 2004 5 3 339-343
15. 549758 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ CIRCULATION 2002 105 18 2159-2165
16. 549759 Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ N ENGL J MED 2004 350 15 1505-1515
17. 550964 Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J AM J CARDIOL 2004 93 12 1487-1494
18. 558529 Ezetimibe + simvastatin (Merck/Schering-Plough). Flores NA CURR OPIN INVESTIG DRUGS 2004 5 9 984-992
19. 570828 HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. Morehouse LA, Sugarman ED, Bourassa P-A, Milici AJ CIRCULATION 2004 110 17 Abs 1168
20. 573518 Pfizer showcases pipeline. Pfizer Inc PRESS RELEASE 2004 November 30
21. 574026 Role of CETP inhibitors in the treatment of dyslipidemia. van der Steeg GK, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJP CURR OPIN LIPIDOL 2004 15 6 631-636
22. 595966 Pfizer's post-Bextra profits tumble 87%. Pfizer Inc PRESS RELEASE 2005 19 April
23. 608248 High density lipoproteins: A new potential therapeutic target for the prevention of cardiovascular disease. Brewer HB Jr ARTERIOSCLER THROMB VASC BIOL 2004 24 3 387-391
24. 608302 HDL and arteriosclerosis: Beyond reverse cholesterol transport. Nofer JR, Kehre B, Fobker M, Levkau B, Assmann G, van Eckardstein A ATHEROSCLEROSIS 2002 161 1 1-16
25. 608306 Regression of atherosclerotic lesions by high density lipoprotein fraction in the cholesterol-fed rabbit. Badimon JJ, Badimon L, Fuster V J CLIN INVEST 1990 85 4 1234-1241
26. 608307 Inhibition of early atherogenesis in transgenic mice by human apoAI. Rubin EM, Krauss RM, Spangler EA, Vertuyft JG, Clift SM NATURE 1991 353 6341 265-267
27. 608312 Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Plump AS, Scott CJ, Breslow JL PROC NATL ACAD SCI USA 1994 91 20 9607-9611
28. 608314 A review of CETP and its relation to atherosclerosis. de Grooth GJ, Klerkx AHEM, Stroes ESG, Stalenhoef AFH, Kastelein JJP, Kuivenhoven JA J LIPID RES 2004 45 11 1967-1974
29. 608317 Monogenic dyslipidemias: Window on determinants of plasma lipoprotein metabolism. Hegele RA AM J HUM GENET 2001 69 6 1161-1177
30. 608318 Genetics of HDL regulation in humans. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez CURR OPIN LIPIDOL 2003 14 3 273-279
31. 608320 A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl transfer protein deficiency. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y PREV MED 1998 27 5 1659-667
32. 608324 Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl transfer protein gene. Agerholm-Larsen N, Nordestgaard BG, Steffensen G, Tybjaerg-Hansen A CIRCULATION 2000 101 16 1907-1912
33. 608327 Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG CIRCULATION 2000 102 18 2197-2203
34. 608328 Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition. An update for clinicians. Forrester JS, Makkar R, Shah PK CIRCULATION 2005 111 14 1847-1854
35. 608334 Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Björjkhem I, Angelin B, Mancuso JP et al ARTERIOSCLER THROMB VASC BIOL 2005 26 5 1-8
36. 608845 Pfizer begins production at torcetrapib/atorvastatin manufacturing facility; major milestone for potential cardiovascular medicine. Pfizer Inc PRESS RELEASE 2005 June 22
37. 612882 HDL revisited: New opportunities for managing dyslipoproteinaemia and cardiovascular disease. Watts GF, Burnett JR CLIN BIOCHEM REV 2004 25 7-18
38. 613751 Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. Lloyd DB, Lira ME, Wood LS, Durham LK, Freeman TB, Preston GM, Qiu X, Sugarman E, Bonnette P, Lanzetti A, Milos PM, Thompson JF J BIOL CHEM 2005 280 15 14918-14922
39. 613753 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol. Davidson M, McKenney J, Revkin J, Shear C J AM COLL CARDIOL 2005 45 3 Suppl A 802-803
40. 614753 Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: An update for clinicians. Forrester JS, Makkar R, Shah PK CIRCULATION 2005 111 14 1847-1854
41. 614757 A review of CETP and its relation to atherosclerosis. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA J LIPID RES 2004 45 11 1967-1974
42. 615444 Pfizer (PFE). Grofik S CITIGROUP SMITH BARNEY 2005 July 18
43. 616461 Torcetrapib and atorvastatin - should marketing drive the research agenda? Avorn J N ENGL J MED 2005 352 25 2573-2576